五味苦参肠溶胶囊减轻小鼠肠道炎症

doi:10.3969/j.issn.1000-8535.2023.08.002

摘要/Abstract

摘要： 目的从炎症反应和肠道屏障两个方面探究五味苦参肠溶胶囊对葡聚糖硫酸钠（DSS）诱导的小鼠结肠炎的治疗作用。方法 6~8周龄雄性BALB/c小鼠被随机分为3组,分别为正常组、急性肠炎模型组和五味苦参组。急性肠炎模型组和五味苦参组小鼠予含有3% DSS的饮用水1周诱导急性结肠炎,其后急性肠炎模型组予PBS灌肠,五味苦参组予五味苦参肠溶胶囊制备为灌肠液灌肠。每天称量小鼠体质量,观察大便性状及血便情况,第8天处死小鼠,取结肠组织检测炎症细胞因子和肠屏障因子。结果与正常组相比,急性肠炎模型组肠道炎症明显,五味苦参组有效缓解肠道炎症和有利于肠上皮屏障修复。表现为五味苦参灌肠液有效缓解小鼠体质量下降,具有较低的DAI评分,有较好的组织学表现,其结肠组织IL-1β,IL-6和TNF-α的相对表达下降,Occludin和ZO-1的相对表达增加（P<0.05）。结论五味苦参肠溶胶囊制备的灌肠液可减轻DSS诱导的小鼠急性结肠炎。

关键词: 五味苦参肠溶胶囊, 葡聚糖硫酸钠, 结肠炎, 炎症因子, 上皮屏障

Abstract: Objective To explore the therapeutic effect of five-flavor sophora flavescens enteric-coated capsules（FSEC）on dextran sulphate sodium（DSS）-induced colitis in mice from inflammatory response and intestinal barrier．Methods Male BALB/c mice aged 6-8 weeks were randomly divided into three groups,namely normal group,acute colitis group and FSEC group．The mice in acute colitis group and FSEC group were given drinking water containing 3% DSS for one week to induce acute colitis,and then they were given PBS enema or FSEC enema respectively．The mice were administered daily,including weight loss,the stool properties and bloody feces．The mice were sacrificed on the 8th day,and the colon tissue was collected to detect inflammatory cytokines and intestinal barrier cytokines．Results Compared with the normal group,the intestinal inflammation in the acute colitis group was obvious,however the FSEC effectively relieved intestinal inflammation and facilitated the intestinal epithelial barrier repair．It showed that FSEC enema effectively relieved weight loss and had a lower disease activity index score．In addition,FSEC enema group had better histological appearance．Compared to acute colitis group,the relative expression of IL-1β,IL-6 and TNF-α in colon tissue decreased,and the relative expression of Occludin and ZO-1 significantly increased in FSEC group（P<0.05）．Conclusions FSEC enema can alleviate DSS-induced acute colitis in mice．

Key words: five-flavor sophora flavescens enteric-coated capsules, dextran sulphate sodium, colitis, inflammatory factors, epithelial barrier

冯碧燕. 五味苦参肠溶胶囊减轻小鼠肠道炎症[J]. 广州医药, 2023, 54(8): 9-16.

FENG Biyan. Five-flavor sophora flavescens enteric-coated capsules alleviate intestinal inflammation in mice[J]. Guangzhou Medical Journal, 2023, 54(8): 9-16.

参考文献

[1] 梁笑楠,尹凤荣,张晓岚.炎症性肠病诊断与治疗的共识意见(2018年,北京)溃疡性结肠炎部分解读[J].临床荟萃,2018,33(11):987-990.
[2] 钱家鸣,杨红.中国炎症性肠病研究的历史回顾现状和展望[J].中国实用内科杂志,2015,35(09):727-730.
[3] TONG Z Q,YANG B,CHEN B Y,et al.A multi-center,randomized,single-blind,controlled clinical study on the efficacy of composite sophora colon-soluble capsules in treating ulcerative colitis[J].Chin J Integr Med,2010,16(6):486-492.
[4] 焦英伟,刘强,余兆惠.复方苦参结肠溶胶囊联合美沙拉嗪对改善溃疡性结肠炎患者生活质量的临床研究[J].山西医药杂志,2019,48(23):2932-2934.
[5] 刘海燕,陈军贤,徐平珍,等.复方苦参结肠溶胶囊治疗溃疡性结肠炎24例[J].中国中西医结合消化杂志,2012,20(2):86-88.
[6] WIRTZ S,POPP V,KINDERMANN M,et al.Chemically induced mouse models of acute and chronic intestinal inflammation[J].Nat Protoc,2017,12(7):1295-1309.
[7] Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers[R].U.S.Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers[R].U.S.Food & Drug Administration,2005.
[8] SUNUWAR L,MEDINI M,COHEN L,et al.Correction to‘The zinc sensing receptor,ZnR/GPR39,triggers metabotropic calcium signalling in colonocytes and regulates occludin recovery in experimental colitis’[J].Philos Trans R Soc Lond B Biol Sci,2016,371(1703):20160331.
[9] KUO W T,ZUO L,ODENWALD M A,et al.The tight junction protein ZO-1 is dispensable for barrier function but critical for effective mucosal repair[J].Gastroenterology,2021,161(6):1924-1939.
[10] FELDMAN G J,MULLIN J M,RYAN M P.Occludin:structure,function and regulation[J].Adv Drug Deliv Rev,2005,57(6):883-917.
[11] LLOYD-PRICE J,ARZE C,ANANTHAKRISHNAN A N,et al.Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases[J].Nature,2019,569(7758):655-662.
[12] HUANG H,FANG M,JOSTINS L,et al.Fine-mapping inflammatory bowel disease loci to single-variant resolution[J].Nature,2017,547(7662):173-178.
[13] MICHIELAN A,D'INCÀ R.Intestinal permeability in inflammatory bowel disease:pathogenesis,clinical evaluation,and therapy of leaky gut[J].Mediators Inflamm,2015(2015):628157.
[14] PIOVANI D,DANESE S,PEYRIN-BIROULET L,et al.Environmental risk factors for inflammatory bowel diseases:An umbrella review of meta-analyses[J].Gastroenterology,2019,157(3):647-659.
[15] NARULA N,MARSHALL J K,COLOMBEL J F,et al.Systematic review and meta-Analysis:Infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids[J].Am J Gastroenterol,2016,111(4):477-491.
[16] HOU W B,SUN W J,ZHANG X W,et al.Five-Flavor sophora flavescens enteric-coated capsules for ulcerative colitis:A Systematic review and meta-analysis of randomized clinical trials[J].Evid Based Complement Alternat Med,2022(2022):9633048.
[17] 赵军. 复方苦参结肠溶胶囊治疗溃疡性结肠炎湿热内蕴证的临床研究[J].中国中医药现代远程教育,2017,15(13):48-49.
[18] 仝战旗,杨波,童新元,等.复方苦参结肠溶胶囊治疗湿热内蕴型溃疡性结肠炎多中心、随机、双盲、对照研究[J].中国中西医结合杂志,2011,31(2):172-176.
[19] 刁凌云,王胜英,皇金萍,等.美沙拉秦缓释颗粒剂联合五味苦参肠溶胶囊治疗溃疡性结肠炎的疗效观察[J].包头医学院学报,2021,37(10):43-48.
[20] 罗丹,高路,仝战旗,等.五味苦参肠溶胶囊对溃疡性结肠炎小鼠炎性因子的影响[J].中华中医药杂志,2018,33(10):4719-4722.
[21] 罗丹,高路,仝战旗,等.五味苦参肠溶胶囊对溃疡性结肠炎小鼠半胱天冬氨酸蛋白酶1、白细胞介素-1β蛋白的影响[J].解放军医学院学报,2018,39(2):140-143,149.
[22] de SOUZA H S,FIOCCHI C.Immunopathogenesis of IBD:current state of the art[J].Nat Rev Gastroenterol Hepatol,2016,13(1):13-27.
[23] PARK J H,PEYRIN-BIROULET L,EISENHUT M,et al.IBD immunopathogenesis:A comprehensive review of inflammatory molecules[J].Autoimmun Rev,2017,16(4):416-426.